Substance / Medication

Indinavir

SNOMED 372529006 UMLS C0376637

Overview

Active Ingredient

indinavir

RxNorm CUI

114289

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

AIDS

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

7 trials linked to this intervention

Total Trials

Recruiting

With Results

Recent Trials

Influence of the MDR1 Genotype on Blood Levels of Indinavir and Saquinavir in Healthy Volunteers

NCT00050180Phase 4Completed81 enrolled

Intermittent ART in Primary HIV Infection

NCT02300623Phase 4Completed12 enrolled

A Pharmacokinetic (PK) Study of a Combination of Indinavir, Ritonavir, and Amprenavir

NCT00148785Phase 4Completed15 enrolled

HIV Infection And Metabolic Abnormalities Protocol 1 (HAMA001)

NCT00192660Phase 4Completed80 enrolled

Effect of Indinavir Plus Two Other Anti-HIV Drugs on Blood Clotting in HIV-Positive Males With Hemophilia

NCT00002386Phase 4Completed55 enrolled

View all 7 trials on ClinicalTrials.gov

Research Evidence

Published studies and systematic reviews

Sort:

Indinavir Increases Midazolam-Glucuronidation in Humans: Identification of an Alternate CYP3A Inhibitor Using an In Vitro to In Vivo Approach.

Tian Dan-Dan, Leonowens Cathrine, Cox Emily J et al. · Drug Metab Dispos · 2019

PMID: 31028057RCTFull text (PMC)

Lack of a pharmacokinetic drug-drug interaction with venlafaxine extended-release/indinavir and desvenlafaxine extended-release/indinavir.

Jann Michael W, Spratlin Vicky, Momary Kathryn et al. · Eur J Clin Pharmacol · 2012

PMID: 22173281RCT

Indinavir-loaded pH-sensitive microparticles for taste masking: toward extemporaneous pediatric anti-HIV/AIDS liquid formulations with improved patient compliance.

Chiappetta Diego A, Carcaboso Angel M, Bregni Carlos et al. · AAPS PharmSciTech · 2009

PMID: 19127436RCTFull text (PMC)

Effect of omeprazole on the plasma concentrations of indinavir when administered alone and in combination with ritonavir.

Tappouni Hiba L, Rublein John C, Donovan Brian J et al. · Am J Health Syst Pharm · 2008

PMID: 18281734RCTFull text (PMC)

Pharmacokinetic and metabolic effects of American ginseng (Panax quinquefolius) in healthy volunteers receiving the HIV protease inhibitor indinavir.

Andrade Adriana S A, Hendrix Craig, Parsons Teresa L et al. · BMC Complement Altern Med · 2008

PMID: 18713456RCTFull text (PMC)

Lack of indinavir-associated nephrological complications in HIV-infected adults (predominantly women) with high indinavir plasma concentration in Abidjan, Côte d'Ivoire.

Danel Christine, Moh Raoul, Peytavin Gilles et al. · AIDS Res Hum Retroviruses · 2007

PMID: 17263634RCTFull text (PMC)

Boosted versus unboosted indinavir with zidovudine and lamivudine in nucleoside pre-treated patients: a randomized, open-label trial with 112 weeks of follow-up (HIV-NAT 005).

Boyd Mark A, Srasuebkul Preeyaporn, Khongphattanayothin Mana et al. · Antivir Ther · 2006

PMID: 16640103RCT

Pharmacogenetic characteristics of indinavir, zidovudine, and lamivudine therapy in HIV-infected adults: a pilot study.

Anderson Peter L, Lamba Jatinder, Aquilante Christina L et al. · J Acquir Immune Defic Syndr · 2006

PMID: 16791115RCT

A pilot, double-blind, placebo-controlled trial of indinavir in patients with ALS.

Scelsa S N, MacGowan D J L, Mitsumoto H et al. · Neurology · 2005

PMID: 15824372RCT

Absence of association between MDR1 genetic polymorphisms, indinavir pharmacokinetics and response to highly active antiretroviral therapy.

Verstuyft Céline, Marcellin Fabienne, Morand-Joubert Laurence et al. · AIDS · 2005

PMID: 16284462RCT

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type: Substance / Medication
Fully Specified Name: Indinavir (substance)
SNOMED CT: 372529006
UMLS CUI: C0376637
RxNorm CUI: 114289

Clinical Data

This intervention maps to 1 entities in the Healos knowledge graph.

Conditions

Biomarkers

Specialists

Symptoms

Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.